Place Raymond Blyckaerts, 13
B-1050 Brussels, Belgium

Opening hours:
Mon to Thu: 10h - 12h30 and 13h30 - 17h
Fri: 10h - 12h30 and 13h30 - 16h


+3226269640
Google maps


Find us on
Google Maps
To subscribe to our newsletter, please click here. If you would like to become an EATG member, please fill in the form here. You can also subscribe to our RSS feed by clicking here.
You can also follow us on one of these media :
TAGS

30/07/2014
HIV inhibitor may also block herpes virus infection

Herpes viruses are stubborn foes. Infections from this family of viruses last a lifetime, causing suffering and even death when dormant viruses come to life. Herpes virus infections also increase the risk of spreading or acquiring HIV. Creating a successful vaccine against two members of the family, the sexually transmitted herpes simplex virus 1 (HSV-1) and 2 (HSV-2), has proven to...

Read more...





30/07/2014
Theraclone announces exclusive agreement with Gilead Sciences for broadly neutralizing HIV antibodies

SEATTLE, Jul 30, 2014 -- Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, announced today that it has entered into an agreement with Gilead Sciences , Inc., under which Gilead received an exclusive license to develop and commercialize products incorporating Theraclone’s broadly neutralizing HIV-antibodies for therapeutic applications in HIV....

Read more...





30/07/2014
Harm reduction prevents HIV, national evidence from Ukraine and Greece shows

Two presentations given at the 20th International AIDS Conference (AIDS 2014), held in Melbourne, Australia, provide significant evidence that harm reduction programmes successfully prevent HIV infection among people who inject drugs (PWID). Other barriers remain, however, to keeping these programmes in place in the long term, and to ensuring that sexual as well as injecting...

Read more...

Source Source: Aidsmap





30/07/2014
Merck & Co sees Q2 profit rocket

Merck & Co has seen earnings more than double for the second quarter of the year, after a vigorous spout of cost-cutting and a one-time gain from AstraZeneca ($741 million), after it bought out the US group's interest in Nexium and Prilosec, helped swell the overall result. The firm booked net income of $2.03 billion, or $0.68 a share, up from the $906 million, or $0.30 a...

Read more...

Source Source: PharmaTimes





29/07/2014
Gay men interested in taking PrEP already report high-risk behaviour

Less condom use anticipated by some men, but few consistent condom users are interested in PrEP Surveys of gay men in the Netherlands and Australia suggest that some would use condoms less frequently if they were taking PrEP – but that these men are generally not using condoms consistently anyway. The data, presented to the 20 th International AIDS Conference in...

Read more...

Source Source: Aidsmap